small cell Latest Research Papers

The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

Translational Oncology ◽

10.1016/j.tranon.2021.101338 ◽

2022 ◽

Vol 17 ◽

pp. 101338

Author(s):

Xinru Chen ◽

Xiangchan Hong ◽

Gang Chen ◽

Jinhui Xue ◽

Jie Huang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Inhibitor ◽

Immune Inflammation

Download Full-text

FLT-PET/CT in Non-Small Cell Lung Cancer Treated With SBRT- A Pilot Study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2021.10.170 ◽

2022 ◽

Vol 112 (2) ◽

pp. e5-e6

Author(s):

S.C. Lewis ◽

A.J. Hope ◽

M. Chan ◽

J. Weiss ◽

H. Raziee ◽

...

Keyword(s):

Lung Cancer ◽

Pilot Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Flt Pet ◽

Pet Ct

Download Full-text

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

ESMO Open ◽

10.1016/j.esmoop.2021.100353 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100353

Author(s):

O. Molinier ◽

B. Besse ◽

F. Barlesi ◽

C. Audigier-Valette ◽

S. Friard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Real World ◽

Small Cell ◽

Small Cell Lung ◽

Term Survival ◽

Long Term Survival ◽

Real World Evidence

Download Full-text

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers

ESMO Open ◽

10.1016/j.esmoop.2021.100334 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100334

Author(s):

R. Zhong ◽

X. Ling ◽

S. Cao ◽

J. Xu ◽

B. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Dendritic Cell ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Safety And Efficacy

Download Full-text

Changes in the expression of membrane type-matrix metalloproteinases genes (MMP14, MMP15, MMP16, MMP24) during treatment and their potential impact on the survival of patients with non-small cell lung cancer (NSCLC)

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2021.112559 ◽

2022 ◽

Vol 146 ◽

pp. 112559

Author(s):

Jacek Pietrzak ◽

Dagmara Szmajda-Krygier ◽

Agnieszka Wosiak ◽

Rafał Świechowski ◽

Katarzyna Michalska ◽

...

Keyword(s):

Lung Cancer ◽

Matrix Metalloproteinases ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Potential Impact ◽

Membrane Type

Download Full-text

Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2021.10.186 ◽

2022 ◽

Vol 112 (2) ◽

pp. e14

Author(s):

A.E. Dohm ◽

J. Tang ◽

M.N. Mills ◽

B.A. Perez ◽

T.J. Robinson ◽

...

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Hot Spot Not Hot Enough? Differences in Local Control for Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Maximum Point Dose within the Planning Target Volume

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2021.10.169 ◽

2022 ◽

Vol 112 (2) ◽

pp. e5

Author(s):

E.L. Braschi ◽

A.N. De Leo ◽

C.G. Morris ◽

A.R. Yeung

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Local Control ◽

Planning Target Volume ◽

Stereotactic Body Radiotherapy ◽

Hot Spot ◽

Target Volume ◽

Small Cell ◽

Maximum Point ◽

Small Cell Lung

Download Full-text

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

ESMO Open ◽

10.1016/j.esmoop.2021.100355 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100355

Author(s):

C. Gridelli ◽

S. Peters ◽

T. Mok ◽

P.M. Forde ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Expert Panel ◽

Performance Status ◽

Small Cell ◽

International Expert ◽

Small Cell Lung ◽

First Line ◽

Ecog Performance Status ◽

Lung Cancer Patients

Download Full-text

Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer

ESMO Open ◽

10.1016/j.esmoop.2021.100354 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100354

Author(s):

L.-K. Chang ◽

Y.-W. Kuo ◽

S.-G. Wu ◽

K.-P. Chung ◽

J.-Y. Shih

Keyword(s):

Lung Cancer ◽

Pericardial Effusion ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Indirect Treatment Comparison of Lurbinectedin vs. Other Second-Line Treatments for Small-Cell Lung Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2021.10.194 ◽

2022 ◽

Vol 112 (2) ◽

pp. e18

Author(s):

B. Rengarajan ◽

R. Hanvesakul ◽

C. Stack ◽

F. Wilson ◽

J. Park ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment

Download Full-text

small cell
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

FLT-PET/CT in Non-Small Cell Lung Cancer Treated With SBRT- A Pilot Study

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers

Changes in the expression of membrane type-matrix metalloproteinases genes (MMP14, MMP15, MMP16, MMP24) during treatment and their potential impact on the survival of patients with non-small cell lung cancer (NSCLC)

Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases

Hot Spot Not Hot Enough? Differences in Local Control for Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Maximum Point Dose within the Planning Target Volume

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer

Indirect Treatment Comparison of Lurbinectedin vs. Other Second-Line Treatments for Small-Cell Lung Cancer

Export Citation Format

small cellRecently Published Documents

TOTAL DOCUMENTS

H-INDEX

The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

FLT-PET/CT in Non-Small Cell Lung Cancer Treated With SBRT- A Pilot Study

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers

Changes in the expression of membrane type-matrix metalloproteinases genes (MMP14, MMP15, MMP16, MMP24) during treatment and their potential impact on the survival of patients with non-small cell lung cancer (NSCLC)

Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases

Hot Spot Not Hot Enough? Differences in Local Control for Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Maximum Point Dose within the Planning Target Volume

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer

Indirect Treatment Comparison of Lurbinectedin vs. Other Second-Line Treatments for Small-Cell Lung Cancer

small cell
Recently Published Documents